Selecting haematological malignancy patients for intravenous immunoglobulin

L. Paxton, C. Hawkins, P. Crispin*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    Prior randomised studies of immunoglobulin replacement therapy have studied mixed populations with or without a history of infections. Immunoglobulin therapy is expensive and in limited supply suggesting that optimising patient selection is of value. In this retrospective study, infection history identified high-risk groups benefiting from treatment. A group of patients without any infection history had a low risk of infection without immunoglobulin.

    Original languageEnglish
    Pages (from-to)1216-1218
    Number of pages3
    JournalInternal Medicine Journal
    Volume46
    Issue number10
    DOIs
    Publication statusPublished - 1 Oct 2016

    Fingerprint

    Dive into the research topics of 'Selecting haematological malignancy patients for intravenous immunoglobulin'. Together they form a unique fingerprint.

    Cite this